Online inquiry

IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10378MR)

This product GTTS-WQ10378MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10378MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ900MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-221
GTTS-WQ12724MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ413MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ12623MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ11194MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ1916MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ13195MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ256MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW